GO:0036027 protein C inhibitor-PLAU complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036027 describes a heterodimeric protein complex formed by protein C inhibitor (SERPINA5) and urokinase-type plasminogen activator (PLAU).
• Formation of the SERPINA5-PLAU complex inhibits the serine protease activity of urokinase-type plasminogen activator, thereby regulating plasminogen activation and pericellular proteolysis.
• The protein C system, including protein C inhibitor, is a multifunctional regulator of coagulation, fibrinolysis, and inflammation.
• Activated protein C-protein C inhibitor complexes are measurable in human plasma and have been studied as biomarkers in peripheral arterial disease and aortic aneurysms.
• SERPINA5 is a member of the serpin superfamily and inhibits multiple serine proteases, including activated protein C and urokinase-type plasminogen activator.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of SERPINA5-PLAU complex function in coagulation and cancer biology.
Description
The protein C inhibitor-PLAU complex (GO:0036027) is a heterodimeric cellular component composed of protein C inhibitor (SERPINA5) and urokinase-type plasminogen activator (PLAU). Protein C inhibitor is a multifunctional serpin that regulates several serine proteases in plasma and tissues, including activated protein C and urokinase-type plasminogen activator. The assembly of this complex is a key molecular event that controls the proteolytic activity of PLAU, a protease central to plasminogen activation and extracellular matrix remodeling. Understanding this complex is important because it links the anticoagulant protein C pathway to the fibrinolytic system, with implications for vascular disease, inflammation, and cancer. Protein C inhibitor circulates in plasma and is also found in various tissues, where it can form complexes with target proteases. The interaction between SERPINA5 and PLAU is a classic serpin-protease inhibitory interaction, resulting in a stable covalent complex that irreversibly inactivates the protease. This complex has been detected in biological fluids and is considered a marker of protease inhibition. The protein C pathway, including protein C inhibitor, is well recognized for its roles in anticoagulation and cytoprotection. Research on GO:0036027 focuses on how the SERPINA5-PLAU interaction modulates urokinase activity in physiological and pathological contexts. Because PLAU is involved in cell migration, tissue remodeling, and tumor invasion, its inhibition by SERPINA5 has broad biological significance. The complex is therefore a point of convergence for coagulation, fibrinolysis, and cancer biology, making it a relevant target for experimental studies using gene editing and proteomic approaches.
protein C inhibitor-PLAU complex At A Glance
| GO ID | GO:0036027 |
|---|---|
| GO term | protein C inhibitor-PLAU complex |
| Ontology | cellular_component |
| Synonym | PCI-PLAU complex; plasma serine protease inhibitor-PLAU complex; protein C inhibitor-uPA complex; protein C inhibitor-U-plasminogen activator complex; protein C inhibitor-urokinase-type plasminogen activator complex; serpin A5-PLAU complex; SERPINA5-PLAU complex |
| Major function | Inhibition of urokinase-type plasminogen activator (PLAU) serine protease activity through complex formation with protein C inhibitor (SERPINA5) |
| Complex type | Heterodimer of SERPINA5 and PLAU |
| Biological context | Coagulation, fibrinolysis, and pericellular proteolysis |
| Related pathway | Protein C pathway and plasminogen activation system |
What Is GO:0036027?
GO:0036027 defines a heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and urokinase-type plasminogen activator (PLAU); formation of the complex inhibits the serine protease activity of urokinase-type plasminogen activator. In other words, it is a molecular assembly where the serpin SERPINA5 binds to and neutralizes PLAU, thereby controlling PLAU-dependent proteolysis.
Why Is protein C inhibitor-PLAU complex Important in Cell Biology?
The protein C inhibitor-PLAU complex is important because it represents a direct molecular link between the anticoagulant protein C pathway and the fibrinolytic system. By inhibiting PLAU, SERPINA5 controls the generation of plasmin and downstream extracellular matrix degradation, which is critical in vascular remodeling, inflammation, and tumor progression. Dysregulation of this complex may contribute to thrombotic and bleeding disorders, and complexes of protein C inhibitor with activated protein C have been detected in patients with peripheral arterial disease and aortic aneurysms. Thus, understanding GO:0036027 provides insight into mechanisms of hemostasis and disease biomarkers.
• Regulates urokinase-type plasminogen activator (PLAU) activity, a key protease in fibrinolysis and cell migration.
• Connects the protein C anticoagulant pathway with the plasminogen activation system.
• Protein C inhibitor (SERPINA5) is a multifunctional serpin that also inhibits activated protein C.
• Complexes of protein C inhibitor with activated protein C are measurable in plasma and associated with vascular disease.
• PLAU inhibition by SERPINA5 may influence cancer invasion and metastasis through reduced pericellular proteolysis.
• The complex is a potential biomarker for thrombotic and vascular disorders.
• Studying this complex helps clarify serpin-protease interactions in hemostasis.
• CRISPR models can test the causal role of SERPINA5 and PLAU in disease.
• The protein C pathway is a target for anticoagulant and cytoprotective therapies.
• Understanding complex formation may guide development of protease inhibitors.
Structure and Composition of protein C inhibitor-PLAU complex
SERPINA5 (protein C inhibitor) as the serpin component
In simple terms: SERPINA5 is the 'trap' protein that catches and stops PLAU.
Protein C inhibitor, encoded by SERPINA5, is a member of the serpin superfamily and is the inhibitory component of the complex. It is a multifunctional serpin that can inhibit several serine proteases, including activated protein C and urokinase-type plasminogen activator. The reactive center loop of SERPINA5 is critical for its interaction with target proteases.
PLAU (urokinase-type plasminogen activator) as the target protease
In simple terms: PLAU is the enzyme that gets inhibited when it binds to SERPINA5.
Urokinase-type plasminogen activator (PLAU) is a serine protease that converts plasminogen to plasmin, leading to extracellular matrix degradation. When PLAU binds to SERPINA5, its catalytic activity is inhibited through formation of a covalent complex. This interaction is part of the regulation of pericellular proteolysis.
Heterodimeric assembly and covalent complex formation
In simple terms: The two proteins stick together to form a stable pair that shuts down PLAU.
The protein C inhibitor-PLAU complex is a heterodimer formed by the non-covalent and then covalent interaction between SERPINA5 and PLAU. The serpin-protease interaction involves cleavage of the reactive center loop of SERPINA5 by PLAU, followed by formation of a stable acyl-enzyme complex that traps the protease. This mechanism is characteristic of serpin inhibition.
Detection of protein C inhibitor complexes in plasma
In simple terms: Doctors can measure these complexes in blood as signs of protease inhibition.
Complexes of protein C inhibitor with activated protein C have been detected in human plasma and studied as biomarkers in peripheral arterial disease and aortic aneurysms. Although the specific SERPINA5-PLAU complex is less commonly measured, the general principle of serpin-protease complexes as biomarkers is established. These complexes reflect the balance between protease and inhibitor activity in vivo.
Key Genes Involved in GO:0036027 protein C inhibitor-PLAU complex
The following genes and proteins are directly or functionally associated with the protein C inhibitor-PLAU complex (GO:0036027) and related pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SERPINA5 | Encodes protein C inhibitor, the serpin component of the complex | Target for studying serpin-protease interactions and inhibition of PLAU |
| PLAU | Encodes urokinase-type plasminogen activator, the protease inhibited in the complex | Central to fibrinolysis, cell migration, and cancer invasion |
| PROC | Encodes protein C, a zymogen activated to activated protein C | Key component of the protein C pathway that interacts with SERPINA5 |
| PROCR | Encodes endothelial protein C receptor, which enhances protein C activation | Modulates the protein C pathway and indirectly affects SERPINA5 availability |
| THBD | Encodes thrombomodulin, a cofactor for protein C activation | Regulates generation of activated protein C, a target of SERPINA5 |
| F5 | Encodes factor V, a cofactor in coagulation | Mutations affect thrombin generation and protein C pathway |
| F2 | Encodes prothrombin, precursor of thrombin | Thrombin activates protein C and is regulated by the pathway |
| PLAT | Encodes tissue-type plasminogen activator | Another plasminogen activator that may be regulated by serpins |
| PLG | Encodes plasminogen, the substrate of PLAU | Downstream effector of PLAU activity |
| SERPINC1 | Encodes antithrombin, a related serpin | Comparative serpin biology and anticoagulant function |
| SERPINE1 | Encodes plasminogen activator inhibitor-1 | Another regulator of plasminogen activators |
| SERPINF2 | Encodes alpha2-antiplasmin | Regulates plasmin activity downstream of PLAU |
| F8 | Encodes factor VIII, a coagulation cofactor | Deficiency causes hemophilia A and affects coagulation balance |
| F9 | Encodes factor IX, a coagulation factor | Deficiency causes hemophilia B |
| GLA | Encodes gamma-carboxylase, required for vitamin K-dependent factors | Affects activation of protein C and other factors |
| VKORC1 | Encodes vitamin K epoxide reductase | Influences vitamin K-dependent carboxylation of protein C |
| FGA | Encodes fibrinogen alpha chain | Fibrinogen is the substrate for thrombin and plasmin |
| FGB | Encodes fibrinogen beta chain | Component of fibrin clots degraded by plasmin |
How Is protein C inhibitor-PLAU complex Regulated?
The formation of the protein C inhibitor-PLAU complex is regulated by the availability and activity of both SERPINA5 and PLAU. SERPINA5 levels can be modulated by inflammatory mediators and hormones, while PLAU activity is controlled by its receptor (PLAUR) and other inhibitors such as SERPINE1. The protein C pathway itself is regulated by thrombomodulin and endothelial protein C receptor, which influence the generation of activated protein C, a target of SERPINA5. Additionally, thrombin activatable fibrinolysis inhibitor (TAFI) can modulate fibrinolysis and may indirectly affect PLAU-mediated processes. The balance between serpins and proteases is therefore critical for hemostatic regulation.
protein C inhibitor-PLAU complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPINA5 | Vascular disease, thrombosis, cancer | SERPINA5 knockout or overexpression in endothelial cells |
| PLAU | Cancer invasion, fibrinolysis | PLAU knockout in cancer cell lines |
| PROC | Thrombophilia, sepsis | PROC knockout mouse models |
| PROCR | Inflammation, thrombosis | PROCR knockout or knock-in models |
| THBD | Atypical hemolytic uremic syndrome | THBD point mutation knock-in |
Vascular disease and thrombosis
Protein C inhibitor complexes with activated protein C have been associated with peripheral arterial disease and aortic aneurysms, suggesting a role in vascular pathology. The protein C pathway is a major regulator of thrombosis, and dysregulation can lead to thrombotic or bleeding disorders. The SERPINA5-PLAU complex may influence fibrinolysis and clot stability, contributing to vascular disease progression.
Cancer and metastasis
PLAU is well known for its role in cancer invasion and metastasis through plasminogen activation and extracellular matrix degradation. Inhibition of PLAU by SERPINA5 may suppress these processes, making the complex relevant to tumor biology. However, direct evidence linking the SERPINA5-PLAU complex to specific cancers requires further study.
Inflammation and coagulation crosstalk
The protein C pathway has anti-inflammatory and cytoprotective functions, and protein C inhibitor modulates this pathway. Complex formation with PLAU may also affect inflammatory cell migration and tissue remodeling. The interplay between coagulation and inflammation is an active area of research.
From protein C inhibitor-PLAU complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SERPINA5 inhibit PLAU in vivo? | SERPINA5 knockout mouse or cell line |
| What is the effect of PLAU deficiency on fibrinolysis? | PLAU knockout mouse |
| Can point mutations in SERPINA5 alter PLAU binding? | Point mutation knock-in of SERPINA5 reactive center loop |
| How does tagged SERPINA5 localize in cells? | Tagged knock-in of SERPINA5 |
| Does overexpression of SERPINA5 reduce cancer cell invasion? | SERPINA5 overexpression in cancer cell lines |
| What is the role of protein C pathway in vascular disease? | PROC or PROCR knockout models |
How to Study the protein C inhibitor-PLAU complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Levels of protein C inhibitor-protease complexes | Biomarker studies in plasma |
| Immunoblotting | Presence of covalent SERPINA5-PLAU complex | In vitro complex formation assays |
| Chromogenic assay | PLAU protease activity | Inhibition kinetics |
| Mass spectrometry | Identification of complex components | Proteomic discovery |
| CRISPR knockout | Loss of gene function | Causal testing in cells |
| CRISPR knock-in | Introduction of specific mutations | Structure-function studies |
| Fluorescence microscopy | Subcellular localization | Imaging of complex formation |
| RNA-seq | Transcriptional changes upon gene editing | Pathway analysis |
Proteomic detection of serpin-protease complexes
Complexes of protein C inhibitor with target proteases can be detected in plasma or cell lysates using immunoblotting or ELISA with specific antibodies. Mass spectrometry-based proteomics can identify covalent serpin-protease complexes. These methods are essential for confirming the presence of the SERPINA5-PLAU complex in biological samples.
Enzymatic activity assays for PLAU
The inhibitory effect of SERPINA5 on PLAU can be measured using chromogenic or fluorogenic substrates specific for urokinase-type plasminogen activator. These assays quantify residual protease activity after incubation with SERPINA5. They are useful for studying the kinetics of complex formation.
CRISPR-based gene editing
CRISPR/Cas9 can be used to generate knockout, point mutation, knock-in, or overexpression models for SERPINA5 and PLAU. These models allow causal testing of gene function in coagulation and cancer. Editing can be performed in cell lines or primary cells.
Imaging and localization studies
Fluorescence microscopy with tagged SERPINA5 or PLAU can reveal where the complex forms in cells. Live-cell imaging can track the interaction dynamics. These approaches complement biochemical assays.
How CRISPR Can Be Used to Study GO:0036027 protein C inhibitor-PLAU complex
Knockout
CRISPR knockout of SERPINA5 or PLAU can abolish expression of the respective proteins, preventing formation of the protein C inhibitor-PLAU complex. Such models are useful to study the consequences of complex loss on fibrinolysis, cell migration, and coagulation. Knockout cell lines can be generated in endothelial or cancer cells.
Point Mutation
Point mutations in the reactive center loop of SERPINA5 can be introduced to test its specificity for PLAU versus other proteases. Similarly, mutations in PLAU's active site can prevent complex formation. These models help dissect the molecular determinants of the interaction.
Knock-in
Knock-in of tagged SERPINA5 or PLAU allows visualization and pull-down of the complex. Knock-in of disease-associated mutations can model human variants. This approach is valuable for studying complex assembly in a physiological context.
Overexpression
Overexpression of SERPINA5 can enhance inhibition of PLAU and reduce downstream plasminogen activation. Overexpression models are used to test whether increased inhibitor levels affect cancer cell invasion or thrombosis. Conversely, overexpression of PLAU can overwhelm SERPINA5 and promote proteolysis.
How EDITGENE Supports protein C inhibitor-PLAU complex Research
Researchers studying protein C inhibitor-PLAU complex-related genes often need to determine whether a candidate gene is causally involved in complex formation, protease inhibition, or disease progression. EDITGENE provides comprehensive CRISPR gene editing services to create precisely tailored cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for protein C inhibitor-PLAU complex research.
Frequently Asked Questions About protein C inhibitor-PLAU complex
What is the protein C inhibitor-PLAU complex?
It is a heterodimeric protein complex of SERPINA5 and PLAU that inhibits the serine protease activity of urokinase-type plasminogen activator.
What genes are involved in the protein C inhibitor-PLAU complex?
The main genes are SERPINA5 (protein C inhibitor) and PLAU (urokinase-type plasminogen activator).
What is the function of GO:0036027?
GO:0036027 describes the formation of a complex that inhibits PLAU protease activity, regulating fibrinolysis and pericellular proteolysis.
How is the protein C inhibitor-PLAU complex formed?
SERPINA5 binds to PLAU and forms a covalent complex through its reactive center loop, trapping and inhibiting the protease.
What diseases are associated with protein C inhibitor complexes?
Protein C inhibitor complexes with activated protein C have been linked to peripheral arterial disease and aortic aneurysms.
Is the protein C inhibitor-PLAU complex a biomarker?
Complexes of protein C inhibitor with proteases can be measured in plasma and may serve as biomarkers of protease inhibition.
How can I study the protein C inhibitor-PLAU complex in the lab?
You can use ELISA, immunoblotting, enzymatic assays, and CRISPR gene editing to study complex formation and function.
What is the role of PLAU in cancer?
PLAU promotes plasminogen activation and extracellular matrix degradation, contributing to cancer invasion and metastasis.
Can CRISPR be used to study SERPINA5 and PLAU?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect their functions.
What is the relationship between protein C inhibitor and the protein C pathway?
Protein C inhibitor is a serpin that inhibits activated protein C and other proteases, modulating the protein C pathway.
Conclusion
The protein C inhibitor-PLAU complex (GO:0036027) is a key molecular assembly that regulates urokinase-type plasminogen activator activity through serpin inhibition. It connects the protein C anticoagulant pathway with fibrinolysis and pericellular proteolysis, with implications for vascular disease and cancer. Studying this complex using CRISPR models and biochemical assays can reveal new insights into hemostasis and disease mechanisms.
References
- 1. Kubier A et al.. 2012. Endogenous anticoagulants.. Top Companion Anim Med 27(2):81-7 PMID: 23031460
- 2. Blomstrand D et al.. 2010. Activated protein C-protein C inhibitor complex in peripheral arterial disease.. Ann Vasc Surg 24(5):588-95 PMID: 20409682
- 3. Norris LA. 2003. Blood coagulation.. Best Pract Res Clin Obstet Gynaecol 17(3):369-83 PMID: 12787532
- 4. Esmon CT. 2003. The protein C pathway.. Chest 124(3 Suppl):26S-32S PMID: 12970121
- 5. Kölbel T et al.. 2006. Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms.. J Vasc Surg 43(5):935-9 PMID: 16678686
- 6. Espana F et al.. 2005. The multifunctional protein C system.. Curr Med Chem Cardiovasc Hematol Agents 3(2):119-31 PMID: 15853699
- 7. Dahlbäck B et al.. 2005. The anticoagulant protein C pathway.. FEBS Lett 579(15):3310-6 PMID: 15943976
- 8. Wu C et al.. 2016. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.. J Thromb Haemost 14(2):366-74 PMID: 26663133
